Lesson plan

KNX-101

KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain. Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor. Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation. KNX-101 is under development by Kinoxis Therapeutics. As of January 2026, it is in the preclinical research stage of development.

Back to article

Article summary

KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain. Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor. Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation. KNX-101 is under development by Kinoxis Therapeutics. As of January 2026, it is in the preclinical research stage of development.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.